Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients

Conclusion: Because of its favorable toxicity profile and its uptake in HER2-positive lesions, this radiopharmaceutical can offer new therapeutic options to patients who have progressed on trastuzumab, pertuzumab, or trastuzmab emtansine, given its difference in mode-of-action. A dose escalation is planned in a subsequent phase I/II study to assess the therapeutic window of this compound (NCT04467515).

Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: DHuyvetter, M., Vos, J. D., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., Aa, F. v. d., Hendrikse, N. H., Eersels, J. L. E., Everaert, H., Gykiere, P., Devoogdt, N., Raes, G., Lahoutte, T., Keyae Tags: Clinical Investigations Source Type: research